Health Care · Pharmaceutical Preparations · NYSE · CIK 1106644 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $1.30Day +8.33%Mkt cap $53M1Y −24.4%Off 52W high −93.2%Vol (1Y) 813.2%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,318 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest1.0% of sh out |
| Days to cover1.0d |
| 13F net flow (QoQ)−0.00% |
| Top-10 13F concentration100.0% |
| Next report (est.)2026-08-14 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$4.0M |
| Earnings (TTM)-$3.5M |
| ROE−20.9% |
| Net margin−76.9% |
| Sales growth 3Y−20.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+7.4% |
| 1Y−24.4% |
| 3Y−91.9% |
| 5Y−99.7% |
| 10Y−99.1% |
| Since incept. (ann.)−25.8% |
Total return through 2026-07-30 · series begins 2005-06-06. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)813.2% |
| Ann. volatility (3Y)476.6% |
| Sharpe (1Y)0.88 |
| Sharpe (3Y)0.43 |
| Max drawdown (1Y)−85.2% |
| Max drawdown (3Y)−96.8% |
| Beta (3Y vs SPY)0.42 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | 12,924 | $7,884 | 0.03% | new |
| RENAISSANCE TECHNOLOGIES LLC | 11,418 | $6,965 | 0.03% | +0.9% |
| CITIGROUP INC | 996 | $608 | 0.00% | new |
| UBS Group AG | 389 | $237 | 0.00% | −24.2% |
| EFG International AG | 40 | $24 | 0.00% | +0.0% |
| DANSKE BANK A/S | 1 | $1 | 0.00% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | −$0.04 | — | $983,536 | −13.4% |
| 2025-12-31 | 2026-04-01 | — | — | $1.2M | +8.1% |
| 2025-09-30 | 2025-11-12 | −$0.17 | — | $756,217 | −31.3% |
| 2025-06-30 | 2025-08-14 | −$0.16 | — | $1.0M | +10.9% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-14 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
